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Abstract
Background: The YAC128 model of Huntington’s disease (HD) shows substantial deficits in motor, learning and
memory tasks and alterations in its transcriptional profile. We examined the changes in the transcriptional profile in
the YAC128 mouse model of HD at 6, 12 and 18 months and compared these with those seen in other models
and human HD caudate.
Results: Differential gene expression by genotype showed that genes related to neuronal function, projection
outgrowth and cell adhesion were altered in expression. A Time-course ANOVA revealed that genes downregulated
with increased age in wild-type striata were likely to be downregulated in the YAC128 striata. There was a
substantial overlap of concordant gene expression changes in the YAC128 striata compared with those in human
HD brain. Changes in gene expression over time showed fewer striatal YAC128 RNAs altered in abundance than in
the HdhQ150 striata but there was a very marked overlap in transcriptional changes at all time points. Despite the
similarities in striatal expression changes at 18 months the HdhQ150 mice showed widespread mHTT and ubiquitin
positive inclusion staining in the striatum whereas this was absent in the YAC128 striatum.
Conclusions: The gene expression changes in YAC128 striata show a very closely matched profile to that of
HdhQ150 striata and are already significantly different between genotypes by six months of age, implying that the
temporal molecular gene expression profiles of these models match very closely, despite differences in the
prevalence of brain inclusion formation between the models. The YAC128 gene expression changes appear to
correlate well with gene expression differences caused by ageing. A relatively small number of genes showed
significant differences in expression between the striata of the two models and these could explain some of the
phenotypic differences between the models.
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Background
Huntington’s disease (HD) is a fatal progressive neurode-
generation with motor, cognitive and psychiatric mani-
festations. It is caused by an expansion of a CAG triplet
repeat in exon 1 of the HTT gene, which is translated to
give an expanded glutamine tract at the N-terminus of
the protein, huntingtin (HTT) [1]. A series of genetic
mouse models of the disease have been generated using
various technologies to give transgenic and knock in
models of the disease that include both truncated and
full-length Htt [2–8]. These models have been tested in
multiple behavioural paradigms and show deficits in
tests of motor ability and in cognitive and behavioural
assessments [5, 9–16].
Changes in gene expression have also been seen in the
brains and other tissues of the mouse models of HD.
These changes show a substantial overlap between the
various mouse models tested and also overlap with gene
expression changes seen in human HD brain [17]. The
profiles of genes with reduced expression appear to
overlap to greater extent between models and between
models and human brain than those with increased ex-
pression [17, 18]. Treatments that alleviate the de-
creased expression can improve the phenotype in
mouse models, whether directed at transcriptional
mechanisms or not [19–23].
The YAC128 model of HD carries a full length human
HTT gene in a GSE70656 artificial chromosome, and ex-
tensive behavioural testing has shown that it displays
substantial phenotypes that correlate with human HD
symptoms from a relatively early age [13, 14, 16, 24, 25]
including affective symptoms [26]. Deficits on the
rotarod were observed from 4 months of age and per-
sisted throughout life, and deficits on the balance beam
occurred from 8 months [27]. In the water maze, re-
duced ability to find the hidden platform was seen at
8–10 months with reversal learning showing deficits
from 4 months [27]. Deficits in reversal learning in a
set-shifting task were seen by 6 months and of extra-
dimensional set-shifting at 16 months [28], although
no implicit learning deficits were observed in these
mice [29]. Despite these early changes in the behavioural
phenotype of the mice, frank neuronal inclusions were
only visible from 15 months of age, although diffuse stain-
ing with antibodies that detect inclusions was seen from
12 months of age [30].
As HD affects the caudate and putamen earliest and
most profoundly and shows substantial gene expression
dysregulation [18] we chose to examine mouse striatum,
as the nearest equivalent, in order to investigate whether
dysregulated gene expression also occurred in the
YAC128 striatum. We examined global gene expression
changes in the striata from wild-type (WT) and transgenic
mice from the YAC128 mouse line at 6, 12 and 18 months.
We observed alterations in gene expression at all time
points, which overlapped with changes seen in human HD
brain and in other mouse models of the disease. We ob-
served that genes downregulated with age in normal mice
tended to be even more decreased in expression in the
YAC128 striata.
Results
The effects of age on gene expression
Between 6 and 12 months, 2469 mRNAs (probesets:
1272 distinct genes) are altered in abundance in the
WT animals and 1266 mRNAs (800 genes) in the
YAC128 animals (nominal p <0.05). Of these, 241
mRNAs (156 genes), more than expected by chance,
occur in both sets (9.8 % and 19.0 % of probesets re-
spectively, p = 0.045). Between 12 and 18 months, more
mRNAs are altered: 2579 mRNA 1352 genes) in WT
mice and 3019 (2211 genes) in YAC128 mice, of which
522 mRNA (398 genes) are common to both cohorts
(20.2 % and 17.3 % of probesets respectively, p <10−4).
The overlapping probesets and corresponding genes
are given in Additional file 1: Table S1. A GO term en-
richment analysis (Table 1, Additional file 2: Table S2)
shows that few pathways show an over-representation
of significantly differentially expressed genes: only transla-
tion (GO:0006412) in the WT 6–12 month striata and cell
adhesion (GO:0007155) in the YAC128 6–12 month stri-
ata are close to significance. Translation does not appear
as even nominally significant in the YAC128 data, nor cell
adhesion in the WT data (Additional file 2: Table S2). Be-
tween 12 – 18 months several processes are significantly
over-represented in both WT and YAC128 striata
(Table 1), including neuronal processes in both cohorts.
Cell adhesion (GO:0007155) is significantly over-
represented in the YAC128 striata over this time period.
Effects of genotype on gene expression
Analysis between genotypes shows that 2557 probesets
(1821 genes) are dysregulated between YAC128 and WT
animals when using data from all time points (nominal
p < 0.05), of which 1151 are up-regulated and 1106 are
down-regulated in the YAC128 striata. Using an FDR
threshold of p > 0.05, 87 probesets are dysregulated
(Table 2), 53 down- and 34 up-regulated. Analysing the
time points individually, at 6 months 1287 (856 genes),
at 12 months 885 (482 genes) and at 18 months 2484
probesets (1514 genes) are altered in expression (nom-
inal p < 0.05; Additional file 3: Table S3). Between 6 and
12 months 148 probesets (118 genes) are altered in
abundance at both times (11.5 % and 6.0 % respectively;
p = 0.02) and between 12 and 18 months there are 223
such probesets (164 genes, 25.2 % and 9.0 % respectively;
p = 0.039) (Additional file 3: Table S3).
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The TANOVA analysis (Fig. 1, Table 3) highlights a set
of 146 probesets (125 genes) dysregulated between geno-
types but also includes the trajectory of change in
expression over time. Seventy-six genes are common to
the TANOVA and LIMMA FDR p < 0.05 analyses. The
TANOVA results show that if the trajectory of gene ex-
pression with increased age is towards decreasing
mRNA abundance, then these genes are much more
likely to be decreased in expression in the striata of
YAC128 mice compared with wild-type: 39 such differ-
entially expressed genes decreased in expression in
YAC128 mice compared with 4 increased in expression.
The opposite is true for genes increased in expression
with age in the YAC128 mouse striatum: these are more
likely to be increased in expression in the YAC128 stri-
ata: 48 increased compared with 22 decreased mRNAs.
The full TANOVA plots of gene expression over time
are given in Additional file 4: Figure S1.
An over-representation analysis using EASE and DAVID
[31, 32] of the differentially expressed genes by TANOVA
does not reveal any over-represented categories, probably
due to the small numbers of genes within each pattern of
change. However, an over-representation analysis of the
full sets of genes identified by LIMMA analysis (Table 4)
shows that the largest number of pathways are identified
by the down-regulated genes and that these are mostly re-
lated to G-protein and other intracellular signalling path-
ways. An examination of the genes that contribute to
these significant processes shows that there are substantial
overlaps of genes amongst these significant categories and
that the most specific pathway highlighted (the smallest)
is GO:0019226, transmission of nerve impulse. Categories
relating to nervous transmission and synaptic events
appear as nominally significant even if they are not
signficant once the FDR correction has been applied
(Additional file 5: Table S4). In order to highlight the
most significant functional relationships in the data we
conducted a DAVID analysis [31, 32] visualised in
cytoscape in Fig. 2. The most interconnected onto-
logical term is membrane and all the other processes
are related to membrane events: these include cell ad-
hesion, neuronal projections, synaptic functions and
transmission of nerve impulse.
Comparison with human HD and other mouse models
A straightforward examination of the overlap between
the YAC128 and HdhQ150 FDR controlled lists of differ-
entially expressed genes shows that more genes are com-
mon to the two lists than might be expected (p <10−4;
Fig. 3a). However this only examines a very small part of
each genelist and the relationship of alterations in gene
expression extends over a much more substantial pro-
portion of the genes surveyed: in addition the simple
analysis above does not take direction of change in gene
expression into account. It is also hard to compare across
species and gene expression platforms. To gain a more de-
tailed understanding of the relationship between the stri-
atal gene expression changes between the YAC128,
Table 1 Pathways altered with age in mouse striatum in YAC128 mice
ID GO term p-value FDR p Count Global
WT 6 - 12 m
GO:0006412 Translation 2.00E-05 0.043 39 317
HD 6 - 12 m
GO:0007155 Cell adhesion 3.03E-05 0.059 32 384
WT 12 - 18 m
GO:0007608 Sensory perception of smell 2.47E-21 2.07E-18 68 1098
GO:0007600 Sensory perception 1.80E-17 1.51E-14 70 1364
GO:0007186 G-protein coupled receptor protein signaling pathway 1.64E-16 1.37E-13 76 1657
GO:0050877 Neurological system process 1.17E-14 9.73E-12 72 1620
GO:0007165 Signal transduction 2.03E-09 1.69E-06 100 3381
GO:0019236 Response to pheromone 5.91E-05 0.049 9 100
HD 12 - 18 m
GO:0042391 Regulation of membrane potential 1.87E-07 0.001 32 105
GO:0055082 Cellular chemical homeostasis 2.69E-06 0.0081 50 221
GO:0048167 Regulation of synaptic plasticity 1.19E-05 0.0371 14 34
GO:0019226 Transmission of nerve impulse 1.37E-05 0.043 15 39
GO:0007155 Cell adhesion 1.77E-05 0.055 87 483
The probesets and genes that were significant over time are given in Table S1 and the full list of pathways in Table S2. Count is the total number of significantly
differentially expressed probesets in the GO category and Global is the number of genes in that GO category.
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Table 2 Probesets dysregulated between genotypes
Gene ID All 6 m 12 m 18 m
p-value log2FC AbsFC p-value log2FC AbsFC p-value log2FC AbsFC p-value log2FC AbsFC
Down in YAC128
Phex 1.13E-05 −0.645 1.564 1.58E-05 −0.649 1.568 2.09E-01 −0.596 1.512 2.84E-02 −0.691 1.615
Gm501 5.08E-05 −0.494 1.408 7.75E-04 −0.374 1.296 8.17E-02 −0.575 1.490 3.91E-02 −0.532 1.446
Plk5 5.08E-05 −0.448 1.364 6.26E-04 −0.358 1.282 2.27E-01 −0.409 1.328 1.29E-02 −0.577 1.492
Galnt13 1.76E-04 −0.442 1.359 3.52E-04 −0.437 1.353 6.91E-01 −0.374 1.296 8.24E-02 −0.516 1.430
Actn2 1.96E-04 −0.765 1.699 1.60E-04 −0.760 1.694 9.21E-01 −0.591 1.506 3.76E-02 −0.944 1.924
Dgat2l6 1.96E-04 −0.311 1.240 2.30E-04 −0.290 1.223 1.00E + 00 −0.230 1.173 1.42E-02 −0.412 1.331
Sec14l3 2.30E-04 −0.413 1.332 2.84E-03 −0.306 1.236 2.09E-01 −0.444 1.360 4.76E-02 −0.490 1.405
Odf4 2.67E-04 −0.384 1.305 8.07E-04 −0.384 1.305 6.37E-01 −0.391 1.311 2.33E-01 −0.377 1.299
Ptprv 9.42E-04 −0.322 1.250 7.77E-03 −0.255 1.193 7.66E-01 −0.314 1.243 1.08E-01 −0.396 1.316
Ddit4l 1.53E-03 −0.407 1.326 1.71E-04 −0.432 1.349 3.78E-01 −0.430 1.348 2.57E-01 −0.359 1.282
Ryr1 1.80E-03 −0.577 1.492 7.51E-04 −0.507 1.421 8.22E-01 −0.464 1.379 2.73E-02 −0.760 1.694
Npl 2.05E-03 −0.277 1.212 4.42E-02 −0.166 1.122 4.02E-01 −0.319 1.247 1.14E-01 −0.348 1.273
Cdc2l6 2.16E-03 −0.278 1.213 3.58E-04 −0.312 1.241 9.98E-01 −0.262 1.199 2.96E-01 −0.260 1.198
Krt9 2.72E-03 −0.393 1.313 2.47E-02 −0.289 1.221 8.22E-01 −0.423 1.341 2.06E-01 −0.468 1.383
Hvcn1 2.72E-03 −0.229 1.172 1.49E-03 −0.232 1.174 1.00E + 00 −0.151 1.110 9.09E-02 −0.305 1.235
Aoah 4.47E-03 −0.197 1.146 1.33E-02 −0.158 1.116 1.00E + 00 −0.210 1.157 2.26E-01 −0.223 1.167
Bmp2 4.57E-03 −0.286 1.219 4.42E-03 −0.263 1.200 3.78E-01 −0.354 1.278 4.72E-01 −0.240 1.181
Clspn 5.34E-03 −0.355 1.279 7.12E-03 −0.271 1.207 6.68E-01 −0.360 1.284 9.09E-02 −0.435 1.352
Kcnk13 8.57E-03 −0.164 1.120 1.79E-02 −0.135 1.098 7.97E-01 −0.203 1.151 4.72E-01 −0.152 1.111
Glul (2 probes) 9.47E-03 −0.170 1.125 7.37E-03 −0.147 1.107 3.79E-01 −0.222 1.166 4.83E-01 −0.142 1.103
Pkp2 1.02E-02 −0.282 1.216 9.44E-04 −0.313 1.242 3.78E-01 −0.370 1.292 7.26E-01 −0.164 1.120
Oprk1 1.48E-02 −0.456 1.372 1.49E-02 −0.307 1.237 1.00E + 00 −0.333 1.260 1.29E-02 −0.728 1.656
Cnr1 1.48E-02 −0.452 1.368 1.49E-02 −0.369 1.291 1.00E + 00 −0.442 1.359 2.09E-01 −0.545 1.459
Gpr155 1.48E-02 −0.329 1.256 6.12E-04 −0.438 1.355 1.00E + 00 −0.243 1.184 5.06E-01 −0.305 1.235
Zfp180 1.55E-02 −0.216 1.161 9.49E-04 −0.256 1.194 1.00E + 00 −0.165 1.121 3.30E-01 −0.226 1.170
Vrk1 1.93E-02 −0.243 1.184 1.58E-02 −0.223 1.167 1.00E + 00 −0.189 1.140 2.49E-01 −0.317 1.245
Farp2 2.05E-02 −0.154 1.112 4.16E-02 −0.123 1.089 1.00E + 00 −0.133 1.097 2.70E-01 −0.204 1.152
Il33 2.10E-02 −0.398 1.318 3.32E-04 −0.358 1.282 8.17E-02 −0.471 1.386 1.38E-01 −0.365 1.288
Tspan2 2.17E-02 −0.327 1.255 1.07E-02 −0.277 1.212 6.81E-01 −0.356 1.280 2.81E-01 −0.349 1.274
Scn4b 2.20E-02 −0.537 1.451 1.81E-03 −0.628 1.545 1.00E + 00 −0.401 1.320 3.58E-01 −0.582 1.497
Sbsn 2.20E-02 −0.183 1.135 1.56E-02 −0.175 1.129 1.00E + 00 −0.150 1.109 3.30E-01 −0.223 1.168
Ube2cbp 2.20E-02 −0.156 1.114 1.02E-02 −0.159 1.116 1.00E + 00 −0.160 1.117 5.38E-01 −0.150 1.110
Ppp1r9b 2.20E-02 −0.148 1.108 9.75E-03 −0.145 1.106 1.00E + 00 −0.080 1.057 1.34E-01 −0.220 1.165
Fn3k 2.20E-02 −0.143 1.104 2.64E-02 −0.121 1.088 7.91E-01 −0.178 1.131 5.71E-01 −0.129 1.094
Gpx6 2.24E-02 −0.652 1.571 2.59E-01 −0.243 1.183 1.00E + 00 −0.519 1.433 2.73E-02 −1.195 2.289
Erbb2ip 2.24E-02 −0.205 1.153 5.15E-03 −0.209 1.156 9.68E-01 −0.236 1.178 5.71E-01 −0.172 1.126
Lrrk2 3.02E-02 −0.372 1.294 4.21E-03 −0.412 1.331 1.00E + 00 −0.273 1.208 3.39E-01 −0.430 1.347
Ppp1r9a 3.21E-02 −0.265 1.201 1.15E-02 −0.269 1.205 1.00E + 00 −0.187 1.139 2.96E-01 −0.338 1.264
Traip 3.82E-02 −0.256 1.195 7.04E-02 −0.171 1.125 1.00E + 00 −0.146 1.106 6.65E-02 −0.453 1.369
Slc1a2 4.13E-02 −0.141 1.103 3.27E-02 −0.126 1.091 1.00E + 00 −0.164 1.120 6.16E-01 −0.133 1.097
Bank1 4.21E-02 −0.240 1.181 2.04E-03 −0.291 1.223 1.00E + 00 −0.131 1.095 2.73E-01 −0.298 1.229
Rnf8 4.72E-02 −0.116 1.084 7.03E-03 −0.130 1.094 1.00E + 00 −0.070 1.050 3.30E-01 −0.147 1.107
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human brain and other mouse model striata we examined
the overlap by direction in ranked bins of the gene expres-
sion differences. The overlap between the top 1000 pro-
besets altered in abundance between the YAC128 striata
and human caudate is substantial (179/1000 probesets,
p = 0.018, 80/674 orthologous genes (that are coding
genes in both species)) [18]. There is also a significant
overlap with human cerebellum (117/1000 probesets,
p = 0.008, 47/674 orthologous genes), human BA4
cortex (124/1000 probesets, p =0.016, 55/674 orthologous
genes) and BA9 cortex (71/1000 probesets, p = =0.025,
32/674 genes). The YAC128 striatal genes altered in abun-
dance overlapped significantly with those seen in the
HdhQ150 striata (272/1000 probesets, p <10−4, 132/779
genes) and also R6/1 (113/1000 probesets, p = 0.001,
103/779 genes) and R6/2 whole brain (65/1000 probe-
sets, p = 0.012, 62/779 genes) [19, 33]. The direction
of these changes is also largely concordant (Fig. 3b).
Conducting the comparison at the individual time-points
reveals that the substantial overlap between the expression
profile of these tissues is already significant at 6 months
and becomes increasingly significant over time (Additional
file 6: Figure S2). A direct comparison of the YAC128 and
HdhQ150 gene expression profiles at the time points for
which gene expression data are available shows that con-
cordance and overlap increase over time although they are
already substantial by 6 months (Fig. 3c). To ensure that
the overlaps observed were not just a result of non-
specific striatal pathology, we compared the YAC128 gene
expression data in this study to that from a study of
MPTP effects on gene expression which also generated
gene expression profiles in mouse striatal tissue [34]. We
detected no significant overlap of genes differentially
expressed between the two studies (19/1000 genes, NS).
Despite the substantial overlap in gene expression pro-
files, there are genes whose variation in expression dif-
fers between the two models. Differences between
genotype and model were assessed using ANOVA. This
was done by fitting a regression model containing the
main effects of genotype and model, together with their
Table 2 Probesets dysregulated between genotypes (Continued)
Up in YAC 128
Tmc3 1.30E-04 0.480 1.395 1.49E-04 0.374 1.296 2.27E-01 0.395 1.315 6.46E-04 0.672 1.593
Polr2a 2.30E-04 0.288 1.221 2.54E-03 0.230 1.173 6.81E-01 0.279 1.214 6.12E-02 0.354 1.278
Il17rb 9.51E-04 0.238 1.179 2.36E-05 0.270 1.206 9.04E-01 0.198 1.147 9.09E-02 0.246 1.186
Fat1 1.27E-03 0.277 1.212 6.20E-04 0.290 1.223 1.00E + 00 0.276 1.211 2.70E-01 0.265 1.201
Ppia (6 probes) 2.16E-03 0.188 1.139 1.65E-03 0.189 1.140 1.00E + 00 0.151 1.110 1.45E-01 0.224 1.168
Lrrn3 2.16E-03 0.280 1.214 7.46E-04 0.310 1.240 9.98E-01 0.290 1.223 4.51E-01 0.240 1.181
Chdh 4.11E-03 0.181 1.134 9.58E-03 0.160 1.117 1.00E + 00 0.177 1.130 2.60E-01 0.207 1.154
Acy3 4.57E-03 0.292 1.224 2.42E-02 0.171 1.126 2.57E-01 0.322 1.250 4.05E-02 0.383 1.304
Stat1 7.72E-03 0.203 1.151 4.04E-02 0.140 1.102 1.00E + 00 0.227 1.170 2.26E-01 0.244 1.184
Smoc1 1.61E-02 0.265 1.202 3.00E-02 0.190 1.141 1.00E + 00 0.257 1.195 1.38E-01 0.348 1.273
Rnf122 2.05E-02 0.186 1.138 9.00E-02 0.112 1.081 1.00E + 00 0.181 1.134 1.45E-01 0.264 1.201
Cited2 2.05E-02 0.246 1.186 1.89E-02 0.225 1.169 1.00E + 00 0.225 1.169 3.64E-01 0.288 1.221
Enpp6 2.05E-02 0.365 1.288 2.66E-02 0.257 1.195 1.00E + 00 0.335 1.261 9.29E-02 0.504 1.418
Spata5 2.29E-02 0.177 1.131 4.76E-03 0.202 1.150 1.00E + 00 0.183 1.135 6.69E-01 0.146 1.107
Htr2a 2.58E-02 0.362 1.285 4.80E-02 0.284 1.218 7.53E-01 0.469 1.384 6.08E-01 0.334 1.260
Arsb (2 probes) 2.61E-02 0.176 1.130 1.13E-02 0.180 1.133 1.00E + 00 0.104 1.075 2.33E-01 0.244 1.185
Grhpr 3.21E-02 0.188 1.139 4.07E-02 0.144 1.105 1.00E + 00 0.152 1.111 1.65E-01 0.270 1.205
Zfp488 3.55E-02 0.236 1.178 5.66E-01 0.040 1.028 2.27E-01 0.331 1.257 7.49E-02 0.338 1.264
Pla2g4a 3.55E-02 0.253 1.191 3.29E-02 0.172 1.127 1.00E + 00 0.251 1.190 1.17E-01 0.335 1.261
Pou6f2 4.02E-02 0.170 1.125 5.31E-02 0.141 1.103 1.00E + 00 0.152 1.111 3.87E-01 0.218 1.163
Eya1 4.21E-02 0.246 1.186 2.01E-02 0.223 1.167 1.00E + 00 0.233 1.175 3.90E-01 0.281 1.215
Ifit1 4.21E-02 0.383 1.304 8.37E-03 0.380 1.301 1.00E + 00 0.388 1.308 4.67E-01 0.382 1.303
Nfe2l3 4.27E-02 0.169 1.125 4.26E-02 0.109 1.079 1.00E + 00 0.067 1.048 1.29E-02 0.332 1.258
Plekhh2 4.72E-02 0.200 1.148 1.95E-05 0.284 1.218 1.00E + 00 0.144 1.105 3.90E-01 0.171 1.126
Mobkl2b 4.82E-02 0.225 1.169 2.45E-02 0.171 1.126 1.00E + 00 0.254 1.192 2.73E-01 0.251 1.190
Probsets annotated to genes with a significant difference (FDR p < 0.05) between the two genotypes are given. Each gene corresponds to a single probeset unless
indicated otherwise, the probeset of lowest p-value for all ages has been quoted in such cases. FC = fold change, AbsFC = absolute fold change.
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interaction term. A significant (p < 0.05) interaction term
was taken as evidence of a difference in gene expression
between models. There were 869 probesets with a sig-
nificant interaction term (p < 0.05) (Table 5, Additional
file 7: Table S5). Examination of enrichment does not
reveal any significant functional pathways identified by
these genes, but the most significant individual gene is
Htt itself.
Comparison of inclusion prevalence between mouse
models
To assess whether the gene expression changes corre-
lated with HTT-specific inclusions in the YAC128 and
HdhQ150 mouse models we examined mutant HTT and
ubiquitin distribution in mouse brain using immunohis-
tochemistry (Fig. 4). All regions of the HdhQ150 mouse
brain showed widespread S830 mutant HTT positive
Fig. 1 Patterns of expression identified using TANOVA. Each different pattern is illustrated by one gene showing a significant change in
expression over time and between genotypes. The gene ID and the Affymetrix probeset ID are given. Expression is given as Log-2 fold change
and the time points are in months. WT = wild-type and HD = YAC128
Table 3 Differentially expressed genes between WT and
YAC128 striata identified using TANOVA
WT
Up NC Down Total
Up 45 (13↓,31↑) 12(3↓,8↑) 16(6↓,9↑) 73(22↓,48↑)
YAC128 NC 10(7↓,2↑) 8(5↓,3↑) 7(4↓,3↑) 25(16↓,8↑)
Down 17(10↓,2↑) 9(8↓,1↑) 22(21↓,1↑) 48(39↓,4↑)
Total 72 29 45 146
Numbers of genes significant for each TANOVA pattern of change over time,
given as number (number of genes down-regulated in YAC128↓,number of
genes up-regulated in YAC128↑): some genes showed a mixed pattern of
change and have not been included. NC = no change. For instance in the top
left hand corner, 45 genes were seen to increase in expression with age in
YAC128 and wild-type striata, and of those 13 were reduced in expression in
WT compared with YAC128 expression and 31 were increased in expression
compared with YAC128 expression.
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inclusions (Fig. 4a). In contrast the YAC128 mouse brain
at 18 months showed few frank inclusions (Fig. 4c),
though there is nuclear filling in all regions and a few
small inclusions in the hippocampus. The HTT in the
Q150 mice is entirely mouse and all mutant, whereas
YAC128s have human mutant HTT and endogenous
mouse HTT. In order to ascertain that the S830 was de-
tecting similar inclusions we also assessed inclusion load
using anti-ubiquitin (Fig. 4b and d). The anti-ubiquitin
antibody also detects the inclusions in the Q150 mouse
brain, though they are less frequent than the S830 posi-
tive inclusions, showing that the inclusions shown by
the HdhQ150 brain are not a direct result of the relevant
mutant HTT epitope only being available to the S830
antibody in the HdhQ150 but not the YAC128 brains.
Discussion
The data demonstrate that the gene expression changes
in the YAC128 mouse striata are similar to those in the
HdhQ150 striata at all ages [35]. These results are
Table 4 GO terms showing over-representation amongst genes differentially expressed in YAC128 compared with WT striata
ID Term FDR p Count Global
Genes down in YAC128
GO:0007186 G-protein coupled receptor protein signaling pathway 2.65E-12 155 1616
GO:0007165 Signal transduction 9.18E-12 256 3253
GO:0003008 System process 1.05E-09 147 1624
GO:0007600 Sensory perception 1.45E-07 125 1364
GO:0007608 Sensory perception of smell 1.26E-06 104 1098
GO:0050801 Ion homeostasis 1.47E-04 34 239
GO:0050789 Regulation of biological process 2.26E-04 379 6038
GO:0055082 Cellular chemical homeostasis 2.35E-04 32 221
GO:0042391 Regulation of membrane potential 7.05E-04 20 105
GO:0007154 Cell communication 2.58E-02 24 218
GO:0019226 Transmission of nerve impulse 3.42E-02 10 39
Genes up in YAC128
GO:0019884 Antigen processing and presentation of exogenous antigen 1.74E-02 8 26
The full list of differentially expressed genes between genotypes is given in Table S3 and the full pathway analysis in Table S4. Count is total number of
significantly differentially expressed probesets in that GO category and Global is the total membership of that GO category.
Fig. 2 Pathways implicated by the gene expression differences in YAC128 mouse striata. List of differentially expressed genes were generated by
t-test using a nominal p < 0.01; DAVID was used for the pathway analysis with a pathway filter q < 0.05. The pathway node size is proportional to
gene membership and the edges joining nodes are weighted by gene overlap between nodes. Terms have been clustered into groups that contain
90 % genetic similarity on average. The most significant term of the cluster has been displayed. These terms have been further clustered at a level of
50 % average genetic similarity and colour-coded by cluster
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Fig. 3 (See legend on next page.)
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directly comparable as samples from mice of the same
age were arrayed on the same chip. The similarity in-
creases with age which is most likely to indicate a con-
vergent gene expression phenotype in the striata of these
models as the effects of the mutation become more
marked and overcome differences between the models.
It also demonstrates that the trajectory of molecular
changes in the striata of these two differently con-
structed model lines parallel each other very well, des-
pite differences apparent in the onset of their
phenotypic changes [27, 28, 36].
The similarities in RNA changes are also paralleled in
the human HD brain, especially in the caudate [18]. It is
unsurprising that the human caudate gene expression
profile should more closely parallel that of the mouse
striatum than those of the human cortex or cerebellum,
as the mouse caudate is contained within the striatal tis-
sue analysed. These data therefore indicate that the gene
expression profiles of these two mouse models of HD
are convergent over time, and this is reinforced by com-
parisons with other models and with human caudate.
One major difference between these two models of
HD is in the development of HTT-positive inclusions
[30, 37]. The YAC128 model develops frank nuclear in-
clusions in the brain relatively late, from 15 months of
age onwards, whereas the HdhQ150 model has such in-
clusions present from 5 months of age. The reason for
this difference is not understood, though it is possible that
the human and mouse proteins show differences in re-
activity to the S830 antibody: however, the ubiquitin im-
munohistochemistry also shows that intranuclear
inclusions are present in the HdhQ150 but not the
YAC128 mouse brain at 5 months. Fewer ubiquitin-
positive inclusions are observed than S830 positive inclu-
sions which is consistent with previous data indicating
that ubiquitin positive staining is a later event than
mutant-HTT positive staining of inclusions in mouse
brain [38]. However, the trajectory of nuclear filling with
mHTT immunoreactivity followed by inclusion formation
is common to both models and thus it seems most likely
that this is a true difference in mHTT aggregation in these
models. The concentrations of mHTT present in the
YAC128 brain are probably similar to that in the
HdhQ150 model as we noted reduced expression of
mHTT in the HdhQ150 model such that it probably only
expresses around half the WT endogenous level in brain
[13, 39]. However, the presence of normal mouse HTT
might inhibit inclusion formation. If endogenous mouse
HTT is recruited into the inclusions then the presence of
heterozygous protein differences is known to slow aggre-
gation of the cognate proteins in other neurodegenerative
diseases where protein inclusions are present in the
disease, for instance in prion-related disease [40, 41].
While we have noted there are strong similarities in the
striatal gene expression changes between these models,
there are also differences, although the differences do not
highlight any specific functional pathways: nevertheless
these differences might contribute to the difference in in-
clusions observed. Discordant inclusion formation and
pathogenic effects have been noted previously in a num-
ber of different systems [42, 43] though the connection
with similar gene expression profiles in the face of differ-
ential inclusion formation has not been made previously.
The significant differences between the gene expres-
sion profiles of the striata from the YAC128 and
HdhQ150 lines do not highlight any obvious functional
differences between the two models that could account
for the observed differences in inclusion prevalence.
Grk4 is close to the Htt locus in mice but it is not con-
tained within the YAC construct used to generate these
mice [13]: thus this cannot explain the increased expres-
sion of this gene. Other than this the significantly altered
genes are not in the same chromosomal locations, so no
chromosomally specific effect can be inferred that is due
to the direct action of the transgene. The gene most
significantly altered in expression is Htt itself and this
is expected in light of the substantial down-regulation
of mHTT in the HdhQ150 homozygous knock in
striata [39].
Most of the genes that are differentially expressed be-
tween the models show increased expression in YAC128
striata and it is possible that this is due to the increased ex-
pression of HTT itself over the endogenous HTT expres-
sion. Mutant HTT can rescue the lethal effects of knocking
out WT HTT [4, 44] so the mutant protein may well be
exerting functional effects in relation to its normal as well
as its pathological function. The expression of the YAC
transgene in the YAC128 animals is close to the level of ex-
pression of the endogenous mouse gene [45]. The differen-
tial changes could potentially be related to the normal
(See figure on previous page.)
Fig. 3 Correlation of direction of expression changes in YAC128 striata, other mouse models of HD and human HD caudate. a shows the overlap
of genes within the FDR adjusteddifferentially expressed genes from the YAC128 compared with the HdhQ150 mouse striata. In B and C
frequency represents the fraction of the top 200 HdhQ150 expression changes that map to a particular bin of ranked data (1000 genes per bin)
in the other dataset, which is then split to concordant or discordant direction of expression change. A higher frequency of concordant (green)
rather than discordant (red) in the first bins indicates a similarity between the YAC128 caudate and other model or human HD gene expression
signature. b shows the comparison of YAC128 striatal gene expression with human HD brain regions [18] and the comparison with other mouse
models and c shows the comparison at the same time points with the HdhQ150 striatal gene expression.
Bayram-Weston et al. BMC Genomics  (2015) 16:1079 Page 9 of 14
function of HTT through the effects of increased overall
huntingtin expression and thus enhancement of the nor-
mal function. The gain in weight of the YAC128 animals
over time compared with most HD mouse models has
been suggested to be the result of the third copy of HTT
and higher huntingtin expression [46]. There is, however,
no overlap with the genes found to be altered in Htt null
cell lines [47], although this could be the result of the very
different biological systems studied and the different chips
used.
Table 5 Genes that show significantly different patterns of differential expression between YAC128 and HdhQ150 striata
Symbol Difference p Q150 FC YAC FC Abs FC diff Description
Actn2 1.07E-03 −0.19 −0.79 0.60 Actinin alpha 2
Htr2a 2.12E-04 −0.15 0.37 0.52 5-hydroxytryptamine (serotonin) receptor 2A
Ifit1 5.88E-03 −0.03 0.41 0.44 Interferon-induced protein with tetratricopeptide repeats 1
Galnt13 5.89E-05 −0.03 −0.45 0.42 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13
Htt 3.19E-10 −0.32 0.09 0.41 Huntingtin
Lgals3bp 9.45E-03 −0.04 0.36 0.40 Lectin, galactoside-binding, soluble, 3 binding protein
Iqub 3.74E-03 −0.33 0.04 0.37 IQ motif and ubiquitin domain containing
Ifi27l1 3.33E-04 −0.06 0.31 0.37 Interferon, alpha-inducible protein 27 like 1
Usp18 1.32E-03 −0.08 0.28 0.36 Ubiquitin specific peptidase 18
Dpp10 2.03E-03 −0.07 0.26 0.34 Dipeptidylpeptidase 10
Pkp2 9.91E-05 0.04 −0.29 0.33 Plakophilin 2
Olfr174 4.74E-03 0.15 −0.18 0.33 Olfactory receptor 174
Trim30 5.90E-04 −0.11 0.21 0.32 Tripartite motif-containing 30
Trpc6 6.67E-03 −0.27 0.02 0.29 Transient receptor potential cation channel, subfamily C, member 6
Zfp185 8.12E-03 −0.09 0.19 0.28 Zinc finger protein 185
Grk4 4.41E-03 −0.06 0.21 0.27 G protein-coupled receptor kinase 4
Acot9 4.17E-04 −0.10 0.17 0.26 Acyl-CoA thioesterase 9
Lgals2 6.58E-03 0.29 0.05 0.25 Lectin, galactose-binding, soluble 2
Rreb1 2.71E-03 −0.11 0.14 0.24 Ras responsive element binding protein 1
Dpysl5 1.39E-03 0.20 −0.04 0.24 Dihydropyrimidinase-like 5
Ceacam2 9.51E-03 −0.16 0.08 0.24 Carcinoembryonic antigen-related cell adhesion molecule 2
Wdr78 5.63E-03 −0.27 −0.03 0.24 WD repeat domain 78
Dnajc5g 5.58E-03 −0.11 0.13 0.23 DnaJ (Hsp40) homolog, subfamily C, member 5 gamma
Ccdc108 8.86E-03 −0.06 0.17 0.23 Coiled-coil domain containing 108
Plac8l1 3.01E-03 0.13 −0.10 0.23 PLAC8-like 1
Rell2 9.35E-03 0.19 −0.04 0.22 RELT-like 2
Tnfsf8 1.67E-03 0.10 −0.12 0.22 Tumor necrosis factor (ligand) superfamily, member 8
Pabpc1l2b 7.47E-03 0.20 −0.01 0.22 Poly(A) binding protein, cytoplasmic 1-like 2B
Slc13a5 7.14E-03 −0.15 0.07 0.21 Solute carrier family 13 (sodium-dependent citrate transporter), member 5
Irf9 1.68E-03 −0.05 0.16 0.21 Interferon regulatory factor 9
Ranbp2 5.60E-03 −0.17 0.04 0.21 RAN binding protein 2
Fut4 7.54E-03 −0.16 0.05 0.21 Fucosyltransferase 4
Tpbg 4.70E-03 0.09 −0.11 0.21 Trophoblast glycoprotein
Rnf213 4.48E-03 −0.01 0.20 0.20 Ring finger protein 213
Speer2 4.22E-03 0.14 −0.06 0.20 Spermatogenesis associated glutamate (E)-rich protein 2
V1rb3 5.18E-03 0.08 −0.12 0.20 Vomeronasal 1 receptor, B3
Setd1b 5.82E-03 0.13 −0.07 0.20 SET domain containing 1B
Dtl 1.26E-03 −0.10 0.09 0.20 Denticleless homolog (Drosophila)
Genes with a significant interaction between YAC128 and HdhQ150 differential gene expression where the absolute fold change difference is > 0.20. FC = fold
change, Abs FC = absolute fold change.
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Htr2a is expressed more highly in the YAC128 than
the HdhQ150 striata. HTR2A in humans is the major
serotonin receptor in the brain and is a target of the
SSRI citalopram, which downregulates its expression
[48–50]. The potentially depressive-like symptoms noted
in the YAC128 animals [26] might therefore relate to al-
terations in the expression of this receptor. The deficits
in the forced swim test in the YAC128 mice are thought
to be a surrogate test for a syndrome related to depres-
sion in mice and this alteration in gene expression might
underlie this observation. The SSRI fluoxetine did not
improve performance in the forced swim task in
YAC128 mice, but this test is confounded in these mice
by the motor deficit and it is not clear that fluoxetine
has the same effects on Htr2a as citalopram. In addition,
the improvement in symptoms seen in mice treated with
SSRIs is thought to be mediated by BDNF levels: it is
possible that these are so compromised in the YAC128
mice that the drugs are incapable of improving them al-
though levels of Bdnf RNA measured in the striata are
unchanged in the cohort of animals that we used. How-
ever, given the prevalence of depressive symptoms in
HD patients [26, 51–53] this may shed light on their
mechanism.
The differences in gene expression with age in these
animals is not the same as for the HdhQ150 animals.
There are fewer changes and they do not highlight as
many pathways, or the same pathways, as in the
HdhQ150 mouse striata, especially between 6 and
12 months [35]. Between 12 and 18 months more path-
ways are highlighted some of which relate to perception
of smell and neurological processes and notably genes
for the perception of smell were enriched between 6 and
12 months in the HdhQ150 cohorts. It is not clear why
these differences exist, and it must be remembered that
these are not true longitudinal data (the same measure-
ments in the same animals) but rather pseudo-longitudinal:
the animals are maintained in the same way and are
on the same genetic background but are different ani-
mals at the different time points. There may be subtle
differences in the housing over time that have contributed
to these differences in striatal gene expression profiles
with age.
Examining the effects of genotype with age using
TANOVA shows that genes that are down-regulated
in the WT animal striata with age are also down-
regulated in the Q150 knock in homozygote striata.
This may indicate that the processes underlying the
down-regulation of gene expression in HD model stri-
ata are related to those in normal ageing. The genes
highlight a number of differentially regulated path-
ways including those involved in G-protein mediated
signal transduction and homeostasis, although there is
no direct overlap with the enriched pathways seen in
the Q150 striata, despite the strong concordant over-
lap in the expression of individual genes [39].
Conclusions
The related pathways of cell adhesion, neuronal projec-
tions, synaptic functions and transmission of nerve im-
pulse seen in the DAVID analysis for enriched pathways
indicates that the maintainance and regulation of con-
nections between neurons is central to the molecular
pathogenesis in YAC128 striatum.
The similarities in striatal gene expression differences
between this HD model and human caudate and with
other mouse models indicate that similar molecular pro-
cesses are probably occurring. These appear to occur des-
pite differences in inclusion formation. This indicates that
the presence of HTT-positive inclusions is not necessary
for these changes to occur. This separation of inclusion
formation from the molecular consequences of the Htt
mutation is worthy of further investigation as many stud-
ies in in vitro systems use inclusion formation as a
Fig. 4 Comparative mutant HTT pathology in the HdhQ150 (panels a, b, e, f) and YAC128 (panels c, d, g, h) mouse brain. Comparative
immunohistochemistry in brains from 18 month old YAC128 or HdhQ150 mice using either the mutant HTT specific antibody S830 or the anti-
ubiquitin at 100x magnification
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measurable end-point to assess the effects of potential
therapeutics.
Methods
Samples
Heterozygous YAC128 mice on a C57BL6/J background
[13] were bred in house and genotypes ascertained using
tail tip DNA (Laragen Inc., Los Angeles). Mice were
culled by cervical dislocation at the same point in the
light phase of the diurnal cycle. CAG repeat lengths in
the YAC128 animals were 121 and no variation from this
was detected. WT and hemizygous YAC128 animals of
both sexes were used in the experiments (57 % male).
The animals were housed as sex matched littermate
groups and had access to food and water ad libitum. All
experiments were carried out in accordance with the
United Kingdom Animals (Scientific Procedures) Act of
1986, and subject to local ethical review (Project licence
PPL30/1968 and PPL30/2305). The behavioural data re-
lating to the complete cohort of mice are given in
Brooks et al. [27].
Gene expression
From this experimental group, 15 hemizygous
YAC128 (7 female and 8 male) and 14 WT (Hdh+/+)
mice (6 female and 9 male) were used for gene ex-
pression studies. Brains from age matched mice from
each genotype were harvested at 6, 12 and 18 months
and micro-dissected into striatum, motor cortex, cere-
bellum, prefrontal cortex and hippocampus. The dis-
sected brain samples were snap frozen in liquid
nitrogen and stored at −80 °C.
Total RNA was extracted from micro-dissected stri-
ata for gene expression analysis as previously described
[19, 35]. RNA quality was determined using an Agilent
RNA 6000 Nano Kit and Agilent 2100 Bioanalyser
(Agilent Technologies, Santa Clara, USA). Samples
with RIN (RNA integrity number) values greater than
7.5 were selected for subsequent analysis. For each
RNA sample, cDNA was generated from 100 ng total
RNA using an Ambion® WT expression kit (Applied
Biosystems Carlsbad, California, USA), followed by
fragmentation, labelling and hybridisation to a Mouse
GeneChip Gene 1.0 ST Array. An Affymetrix WT
Terminal Labelling and Hybridisation kit was used ac-
cording to the manufacturer’s protocol. Gene Chips
were processed using a Fluidics station 450 and a Gene-
Chip scanner 3000 7G (Affymetrix UK Ltd, High
Wycombe UK).
Statistical methods
Gene expression analysis
An analysis of GeneChip expression data was under-
taken using R/Bioconductor. Expression values were
computed using robust multichip average (RMA) (affy
package [54]), with testing for differential gene expression
by age or genotype performed using moderated t-tests in
LIMMA [55]. Changes in gene response over time were
identified using TANOVA [56]. Genes with a false discov-
ery rate (FDR) [57] corrected p < 0.05 were extracted and
the data for these genes classified in three patterns repre-
senting an up, no change or down difference in expression
over the time course (this was done separately for the WT
and YAC128 animals tagging each gene with its highest
correlation to theoretical expression profiles). The gene
expression data are available through GEO accession
number GSE70656.
Determining biological themes
The resultant gene lists from the differential gene ex-
pression, time course ANOVA and behaviour/expression
correlation were analysed for over-representation of
genes in pathways against GO Biological Process gene
sets using the Bioconductor GOstats package with the
conditional hypergeometic test (which only uses those
terms that were not already significant when testing a
higher order (parent) term). Changes in expression of
genes in GO gene sets were assessed using Gene Set
Analysis [58] against the whole dataset. The biological
themes were further analysed using the DAVID
database [31, 32] (with the appropriate background
gene list selected for the make of microarray at the
website). An input list was chosen for all probesets sig-
nificantly differentially expressed at a nominal p-value
< 0.01. The output from this and visualised on
Cytoscape (version 2.8.3) [59, 60], via the Enrichment
Map plugin.
Comparison with other gene expression data
Comparison with differentially expressed genes from
human HD brain [18] and other HD models [19, 33]
was calculated using hypergeometric tests on the top
1000 ranked genes in gene lists for differently
expressed genes between WT and YAC128. To en-
able comparisons between different array platforms
where the species was identical, probesets in gene
lists were first converted to unique EntrezGene IDs
and the overlap calculated using these. Where over-
laps were made between data for different species,
data was first converted to Entrez Gene IDs and
then to Homologene IDs which were used to calcu-
late the overlap between lists. In addition, a graph-
ical representation of the overlap, along with
information about the relative direction of changes
was generated using the method of Kuhn [17]. Genes
differentially expressed between YAC128 and
HdhQ150 striata were identified by a significant
interaction term in the ANOVA.
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Histology
Tissue was processed and immunohistochemistry carried
out as previously [61]. The ubiquitin antibody was
Mouse anti-ubiquitin from Invitrogen used at a dilution
of 1/1000 in TBS which stains huntingtin positive inclu-
sions [62]. S830, which recognises mutant HTT was a
kind gift from Gillian Bates [63].
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